On the one hand, these boost antitumoral response by targeting membrane-bound LAG-3 in T cells, the most current example being the drug relatlimab, showing interesting effectivity when combined with an anti PD-1 agent in a phase III trial for metastatic melanoma [27]. The gene discussed is LAG3; the disease is metastatic melanoma.